| | Comparison group | Outcomes | Study ID | Sample size I/C (events) | Effect estimation [95% CI] | P (α = 0.05) |
| | CHM vs. drugs | Pain score (VAS) | Total | 45/48 | MD −0.87 [−1.69, −0.04] | 0.04 | | Jiang F, 2009 | 30/30 | MD −1.04 [−2.05, −0.03] | 0.04 | | Meng L, 2006 | 15/18 | MD −0.52 [−1.96, 0.92] | 0.48 | | Cure rate (end of treatment) | Total | 45/48 (35/23) | RR 1.58 [1.13, 2.22] | 0.008 | | Meng L, 2006 | 15/18 (11/9) | RR 1.38 [0.78, 2.43] | 0.18 | | Jiang F, 2009 | 30/30 (24/14) | RR 1.71 [1.12, 2.62] | 0.01 |
| | CHM + drugs vs. drugs | Pain score (VAS) | Shao Z, 2011 | 18/16 | MD −0.47 [−1.38, 0.44] | 0.31 | | Duration of pain (days) | Total | 73/71 | MD −9.19 [−16.73, −1.65] | 0.02 | | Duan XW, 2011 | 10/10 | MD −16.00 [−23.32, −8.68] | <0.0001 | | Wang Q, 2014 | 35/35 | MD −1.70 [−2.80, −0.60] | 0.003 | | Pan HR, 2010 | 10/10 | MD −16.00 [−23.32, −8.68] | <0.0001 | | Shao Z, 2011 | 18/16 | MD −5.46 [−10.89, −0.03] | 0.05 | | Incidence of PHN | Total | 101/101 (10/21) | RR 0.49 [0.25, 0.99] | 0.05 | | Liang FL, 2012 | 30/30 (3/9) | RR 0.33 [0.10, 1.11] | 0.07 | | Yu F, 2013 | 36/36 (6/9) | RR 0.67 [0.26, 1.68] | 0.39 | | Wang Q, 2014 | 35/35 (1/3) | RR 0.33 [0.04, 3.05] | 0.33 | | Cure rate (end of treatment) | Total | 112/112 (62/44) | RR 1.40 [1.08, 1.82] | 0.01 | | Duan XW, 2011 | 10/10 (10/6) | RR 1.62 [0.97, 2.69] | 0.06 | | Zeng L, 2005 | 18/20 (10/8) | RR 1.39 [0.71, 2.73] | 0.34 | | Liang FL, 2012 | 30/30 (10/8) | RR 1.25 [0.57, 2.73] | 0.57 | | Shao Z, 2011 | 18/16 (11/4) | RR 2.44 [0.97, 6.17] | 0.06 | | Yu F, 2013 | 36/36 (21/18) | RR 1.17 [0.76, 1.79] | 0.48 | | Quality of life (WHOQOL-100) | Total | 94/57 | MD 4.72 [0.45, 8.98] | 0.03 | | Shao Z, 2011 | 18/16 | MD 7.59 [1.06, 14.12] | 0.02 | | Wu JL, 2011 | 76/41 | MD 3.07 [−1.55, 7.69] | 0.19 | | AM vs. drugs | Pain score (VAS) | Liu ZW, 2013 | 30/30 | MD −1.10 [−1.70, −0.50] | 0.0003 | | Duration of pain (days) | Liu ZW, 2013 | 30/30 | MD −5.87 [−7.85, −3.89] | <0.00001 | | Cure rate (end of treatment) | Total | 70/50 (46/16) | RR 1.99 [1.18, 3.36] | 0.01 | | Liu ZW, 2013 | 30/30 (18/11) | RR 1.64 [0.94, 2.85] | 0.08 | | Li M, 2000 | 40/20 (28/5) | RR 2.80 [1.28, 6.14] | 0.01 |
|
|
Note: CHM – Chinese herbal medicine, AM – acupuncture and moxibustion, MD – mean difference, CI – confidence interval, RR – risk radio, and PHN – postherpetic neuralgia.
|
